New imaging modalities to consider for men with prostate cancer on active surveillance
Crossref DOI link: https://doi.org/10.1007/s00345-021-03762-x
Published Online: 2021-06-19
Published Print: 2022-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bhanji, Yasin
Rowe, Steven P.
Pavlovich, Christian P. http://orcid.org/0000-0002-8532-0251
Text and Data Mining valid from 2021-06-19
Version of Record valid from 2021-06-19
Article History
Received: 25 January 2021
Accepted: 10 June 2021
First Online: 19 June 2021
Declarations
:
: Steven P. Rowe receives research funding and serves as a Consultant to Progenics Pharmaceuticals, Inc., the licensee of 18F-DCFPyl.